A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer

Stopped early · Phase 1/Phase 2

Conditions studied: Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer

In brief

The main aim of this study is to check for side effects and tolerability of TAK-186 (also known as MVC-101) in adults with unremovable advanced or metastatic cancer. Another aim is to characterize and evaluate the activity of TAK-186 (MVC-101). Participants may receive treatment throughout the study for a maximum of 13 months and will be followed up at 30 days and 90 days and then every 12 weeks for up to 48 weeks after the last treatment.

Key facts

Study ID
NCT04844073
Run by
Takeda
People needed
95
Starts
2021-03-08
Expected to finish
2025-06-17
Last updated by the study team
2025-12-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.